English abstract
One of the central issues in the treatment of patients with diabetes is whether tight glycemic control will reduce Cardiovascular Disease (CVD) morbidity and mortality. The Diabetes control and complications trial (DCCT) conclusively showed that the greater the average blood glucose in patients with type 1 diabetes, the greater the risk of developing neuropathy, retinopathy and nephropathy.1 The Diabetes control and complications trialEpidemiology of Diabetes Interventions Complications (DCCT- EDIC) trial showed that a history of tight glycemic control significantly reduces the rate of CVD.2
